Outcomes and toxicity in re-irradiation of gynecologic cancer: Systematic review of the Italian association of radiation and clinical oncology (AIRO)

• Published in: Gynecologic oncology Vol. 179; pp. 33 - 41
• Main Authors: Critelli, Paola, Pezzulla, Donato, Lillo, Sara, Arpa, Donatella, Scricciolo, Melissa, Di Carlo, Clelia, Argenone, Angela, Borzillo, Valentina, Marsella, Anna Rita, Tamburo, Marinella, Di Franco, Rossella, Di Marzo, Alessandra, Settineri, Nicola, Mondello, Stefania, Macchia, Gabriella, Belgioia, Liliana, Cerrotta, Annamaria, Pontoriero, Antonio
• Format: Journal Article
• Language: English
• Published: United States 01.12.2023
• Subjects: Female; Genital Neoplasms, Female - radiotherapy; Humans; Italy; Medical Oncology; Neoplasm Recurrence, Local - pathology; Re-Irradiation - adverse effects; Re-Irradiation - methods; Italy
• ISSN: 0090-8258; 1095-6859; 1095-6859
• DOI: 10.1016/j.ygyno.2023.10.016

The aim of this study was to provide a literature review on the efficacy and safety of reirradiation(re-I) of locoregional recurrences in gynecological malignancies. A computerized literature search was performed in 4 electronic databases (1993-2020). Random-effects models and a tendency towards high heterogeneity (Cochran Q chi-square test and the I statistic) were used. A meta-analysis technique over single and multi-arm studies was performed to determine the pooled acute and late toxicity rate ≥ G3, locoregional control (LC), and overall survival (OS). Out of 178 articles, only 18 articles accounting for 820 patients (pts) met the inclusion criteria. Outcomes were evaluable for 522 patients. Subgroup analyses highlighted moderate to high heterogeneity among studies. BT (Brachytherapy) showed a 2y OS of 63% (95% CI, 55 to 71 p = 0,36) and 5y OS of 42% (95% CI, 35 to 50, p = 0,43) with 1y-2y-3y LC of 74 (95% CI, 62 to 75, p = 0.04)49% (95% CI, 40 to 58, p = 0.38) and 48% (95% CI, 39 to 58, p = 0,45) respectively. Chemotherapy does not improve SBRT outcomes: BT showed a G3- G4 toxicities rate was of26% (95% CI: 8-49%); studies on SBRT re-I showed a G3-G4 toxicity around of 20% if combined with CHT, and <10 when alone. A large heterogeneity among studies was revealed, but showing promising results in terms of safety and feasibility. BT resulted the best kind of radiation therapy delivery in terms of clinical outcome and comparable to the SBRT technique in terms of toxicities.